Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -
- 新型CDK2/9抑制剂fadraciclib引发了一个新的针对癌症的作用机制 -
BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC). The data show that fadraciclib substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDX). The data were presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.
新泽西州伯克利高地，2024年6月4日（环球新swire） - 生物药公司Cyclacel Pharmaceuticals, Inc.（纳斯达克:CYCC，纳斯达克:CYCCP，"Cyclacel"或"公司"）正在开发基于癌细胞生物学的创新药物，今天宣布独立研究者展示了fadraciclib的临床前数据，该药物是该公司的环状依赖性激酶（CDK）2/9抑制剂，作为一种新的治疗转移性结直肠癌（CRC）的疗法具有治疗潜力。数据显示，fadraciclib在CRC患者源性器官样和异种移植物中能够显著抑制生长，触发细胞凋亡，引发分裂期灾难。该数据在美国临床肿瘤学协会（ASCO）年度会议于2024年5月31日至6月4日在伊利诺伊州芝加哥市的海报展示中披露。
